India Equity Research | Auto & Auto Ancillaries October 29, 2020 Result Update

Hero Motocorp

Refer to important disclosures at the end of this report

Strong quarter; volume growth to improve going ahead

CMP: Rs 2,894 as of (October 29, 2020) TP: Rs 3,839 (▲)

Rating: BUY (∎) U

Upside: 32.6 %

- Q2FY21 revenue grew strongly by 24% yoy to Rs93.7bn and EBITDA surged 17% to Rs12.9bn, broadly in line with estimates. Though EBITDA margin contracted 80bps due to the BS6 transition impact, EBITDA/unit came in at a three-year high of Rs7,089.
- After a 33% wholesales decline in H1FY21, we expect a turnaround in H2FY21/FY22E with growth of 21%/16%, owing to strong rural demand, pickup in urban demand, shift toward personal mobility and favorable base effect.
- HMCL is well-placed to benefit from a 2W upcycle due to its strong rural presence. Over FY20-23E, we expect a pick-up in earnings growth (10% CAGR), robust ROCEs (~30%) and strong FCFs (~Rs34bn/year).
- Valuations are reasonable (15x/14x FY22/23E EPS) compared with a historical multiple of 18x. Reaffirm Buy with a revised TP of Rs3,839, based on 18x FY23E EPS (Sep'22E earlier) and value of Hero FinCorp at Rs93/share.

Strong revenue/EBITDA performance: Revenue grew strongly by 24% yoy to Rs93.7bn (est.: Rs95.2bn) and EBITDA grew 17% to Rs12.9bn (est.: Rs13.2bn), broadly in line estimates. Volumes grew by 7% to 1.8mn units, while realization grew by 15% to Rs51,620. EBITDA margin contracted 80bps to 13.7% (est.: 13.9%) due to the BS6 transition impact, but EBITDA/unit increased by 5% to Rs7,089 (a 3-year high). Overall, adjusted PAT grew by 4% to Rs9.5bn (est.: Rs10.2bn), slightly below our estimates due to lower other income (down 32% to 1.4bn). Share of profits from associates (Ather Energy and Hero Fincorp) stands at Rs130mn vs. 140mn in Q2FY20.

Festive season update: Retails have been at 96% of last year levels in initial 10 days, which contributes one-third of volume. Management expects improvement in the remaining festive period, led by continued rural growth, better urban/suburban demand and finance availability.

Retain Buy: HMCL has the best rural presence among peers, with dominant market share in Top-7 rural states (which have the urbanization rate below 30%), and a pan-India distribution network with more than 7,200 outlets. We have increased FY21E EPS by 4% to Rs141.5, owing to a rise in volume estimates, but broadly retain FY22E/23E EPS at Rs187.2/Rs209.6. Over FY20-23E, we expect a healthy earnings recovery (10% CAGR), strong ROCEs (~30%) and strong FCF generation (~Rs34bn/year). We retain Buy with a revised TP of Rs3,839, based on 18x FY23E EPS (Sep'22E earlier) and value of Hero FinCorp at Rs93/share. Key downside risks include lower-than-expected volumes, heightened competition, lack of pricing discipline in the industry and higher commodity prices, among others.

Please see our sector model portfolio (Emkay Alpha Portfolio): Automobiles & Auto Ancillaries (page 9)

Financial Snapshot (Standalone)


	=				
(Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
Revenue	336,505	288,361	305,704	363,495	398,246
EBITDA	49,301	39,580	38,560	50,402	56,123
EBITDA Margin (%)	14.7	13.7	12.6	13.9	14.1
APAT	33,849	31,841	28,260	37,391	41,873
EPS (Rs)	169.5	159.4	141.5	187.2	209.6
EPS (% chg)	(8.5)	(5.9)	(11.2)	32.3	12.0
ROE (%)	27.5	23.6	19.7	24.6	25.3
P/E (x)	17.1	18.2	20.5	15.5	13.8
EV/EBITDA (x)	10.7	12.7	12.9	9.6	8.4
P/BV (x)	4.5	4.1	4.0	3.7	3.4
0 0 5 1 5					



Change in Estimates

			0 4)/0 4
EPS Chg FY22E/F		%) (0.4)/0.4
Target Price chang			3.7
Target Period (Mon	iths)		12
Previous Reco			BUY
Emkay vs Consen	sus		
EPS E	Estimat	es	
	F	Y22E	FY23E
Emkay	1	187.2	209.6
Consensus	1	172.3	200.2
Mean Consensus T	P (12N	1) R	s 3,113
Stock Details			
Bloomberg Code		F	IMCL IN
Face Value (Rs)			2
Shares outstanding	ı (mn)		200
52 Week H/L		3,39	5 / 1,475
M Cap (Rs bn/USD	bn)	57	8 / 7.80
Daily Avg Volume (nos.)	1,	736,417
Daily Avg Turnover	(US\$ n	nn)	70.3
Shareholding Patt		m 120	
Promoters	em se	p 20	24.00/
			34.8%
FIIs			33.3%
DIIs			22.9%
Public and Others			9.1%
Price Performance	e		
(%) 1M	3M	6M	12M
Absolute (9)	4	47	7
Rel. to Nifty (12)	-	20	8

Relative price chart



Source: Bloomberg

This report is solely produced by Emkay Global. The following person(s) are responsible for the production of the recommendation:

Raghunandhan N L

raghunandhan.nl@emkayglobal.com +91 22 6624 2428

Mumuksh Mandlesha

mumuksh.mandlesha@emkayglobal.com +91 22 6612 1334


Source: Company, Emkay Research

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Hero Motocorp (HMCL IN)


Story in Charts

Exhibit 1: Volume grew 7% yoy to 1,814,683 units





Source: Company, Emkay Research

Exhibit 3: Revenue/unit grew 15% yoy to 51,620, led by BS6 transition and price hikes





Source: Company, Emkay Research





Source: Company, Emkay Research







Source: SIAM, Emkay Research



Exhibit 4: Gross margin declined 340bps yoy due to BS6 transition



Source: Company, Emkay Research






Exhibit 7: Changes in estimates

Rs mn		FY2	21E			FY2	2E		FY23E				
N3 IIII	Earlier	Revised	% Change	% YoY	Earlier	Revised	% Change	% YoY	Earlier	Revised	% Change	% YoY	
Volumes	5,598,624	5,850,067	4.5	(8.7)	6,793,060	6,762,195	(0.5)	15.6	7,240,836	7,264,599	0.3	7.4	
Net Sales	287,063	305,704	6.5	6.0	357,030	363,495	1.8	18.9	386,982	398,246	2.9	9.6	
EBITDA	35,535	38,560	8.5	(2.6)	49,067	50,402	2.7	30.7	53,940	56,123	4.0	11.3	
Margin (%)	12.4	12.6	21 bps	(111) bps	13.7	13.9	17 bps	125 bps	13.9	14.1	19 bps	23 bps	
APAT	27,072	28,260	4.4	(11.2)	37,540	37,391	(0.4)	32.3	41,698	41,873	0.4	12.0	
EPS (Rs)	135.5	141.5	4.4	(11.2)	187.9	187.2	(0.4)	32.3	208.8	209.6	0.4	12.0	

Source: Company, Emkay Research

Exhibit 8: Volume assumptions

Volume (units)	FY17	FY18	FY19	FY20	FY21E	FY22E	FY23E
Domestic Motorcycles	5,693,681	6,499,051	6,893,688	5,828,782	5,308,218	6,135,972	6,585,745
Growth (%)	1.6	14.1	6.1	(15.4)	(8.9)	15.6	7.3
Export Motorcycles	140,579	178,156	187,185	161,567	164,798	209,294	232,316
Growth (%)	5.9	26.7	5.1	(13.7)	2.0	27.0	11.0
Domestic Scooters	789,974	883,667	719,087	402,676	362,408	398,649	426,555
Growth (%)	(3.5)	11.9	(18.6)	(44.0)	(10.0)	10.0	7.0
Export Scooters	39,812	26,319	20,871	16,694	14,642	18,280	19,983
Growth (%)	(48.6)	(33.9)	(20.7)	(20.0)	(12.3)	24.9	9.3
Total Volume	6,664,046	7,587,193	7,820,831	6,409,719	5,850,067	6,762,195	7,264,599
Growth (%)	0.5	13.9	3.1	(18.0)	(8.7)	15.6	7.4
Realization/unit (Rs)	42,766	42,480	43,027	44,988	52,257	53,754	54,820
Growth (%)	(0.3)	(0.7)	1.3	4.6	16.2	2.9	2.0
Revenue (Rs/unit)	285,005	322,305	336,505	288,361	305,704	363,495	398,246
Growth (%)	0.2	13.1	4.4	(14.3)	6.0	18.9	9.6

Exhibit 9: Actual vs. Estimates (Q2FY21)


(Do mn)	Actual	Esti	imates	% Va	riation	Comment
(Rs mn)	Actual	Emkay	Consensus	Emkay	Consensus	Comment
Total Revenue	93,673	95,181	87,635	(1.6)	6.9	Broadly in line with estimates
EBITDA	12,864	13,214	12,044	(2.6)	6.8	
EBITDA Margin (%)	13.7	13.9	13.7	(15) bps	(1) bps	Broadly in line with estimates
Adjusted net profit	9,535	10,187	9,642	(6.4)	(1.1)	Below estimates due to lower other income (-32% yoy)
Source: Bloomberg, Comp	any, Emkay R	esearch		•		•

Exhibit 10: Quarterly financial summary

Rs mn	Q2FY20	Q3FY20	Q4FY20	Q1FY21	Q2FY21	YoY (%)	QoQ (%)	FY21 YTD	FY20 YTD	YoY (%)
Revenue	75,707	69,967	62,384	29,715	93,673	23.7	215.2	123,389	156,010	(20.9)
Expenditure	64,696	59,578	55,785	28,635	80,809	24.9	182.2	109,444	133,419	(18.0)
as % of sales	85.5	85.2	89.4	96.4	86.3			88.7	85.5	
Consumption of RM	51,257	46,598	43,200	20,939	66,600	29.9	218.1	87,539	107,177	(18.3)
as % of sales	67.7	66.6	69.2	70.5	71.1			70.9	68.7	
Employee Cost	4,689	4,697	4,354	3,824	5,112	9.0	33.7	8,936	9,366	(4.6)
as % of sales	6.2	6.7	7.0	12.9	5.5			7.2	6.0	
Other expenditure	8,750	8,282	8,231	3,872	9,097	4.0	135.0	12,969	16,877	(23.2)
as % of sales	11.6	11.8	13.2	13.0	9.7			10.5	10.8	
EBITDA	11,011	10,390	6,599	1,081	12,864	16.8	1,090.6	13,945	22,591	(38.3)
Depreciation	2,034	2,037	1,747	1,708	1,732	(14.9)	1.4	3,439	4,395	(21.8)
EBIT	8,977	8,352	4,852	(627)	11,133	24.0	(1,875.3)	10,506	18,196	(42.3)
Other Income	2,078	1,822	1,695	1,485	1,413	(32.0)	(4.8)	2,898	4,267	(32.1)
Interest	77	59	41	63	46	(39.5)	(25.9)	109	120	(9.5)
РВТ	10,979	10,115	6,506	795	12,500	13.9	1,472.5	13,294	22,342	(40.5)
Total Tax	1,781	1,311	299	182	2,965	66.5	1,530.9	3,147	5,512	(42.9)
Adjusted PAT	9,198	8,804	6,207	613	9,535	3.7	1,455.1	10,148	16,830	(39.7)
Extra ordinary items Loss/(Gain)	450	0	0	0	0			0	(4,491)	
Reported PAT	8,748	8,804	6,207	613	9,535	9.0	1,455.1	10,148	21,321	(52.4)
Adjusted EPS	43.8	44.1	31.1	3	48	9.0	1,455.1	51	107	(52.4)

Margins (%)						(bps)	(bps)			(bps)
EBIDTA	14.5	14.8	10.6	3.6	13.7	(81)	1,010	11.3	14.5	(318)
EBIT	11.9	11.9	7.8	(2.1)	11.9	3	1,399	8.5	11.7	(315)
EBT	14.5	14.5	10.4	2.7	13.3	(116)	1,067	10.8	14.3	(355)
PAT	12.1	12.6	9.9	2.1	10.2	(197)	812	8.2	10.8	(256)
Effective Tax rate	16.2	13.0	4.6	22.9	23.7	750	85	23.7	24.7	(100)

Source: Company, Emkay Research






Exhibit 12: Peer comparison

Commoniae	СМР	Target	Mcap (Rs bn)	Deee		PE (x)		EV/	'EBITDA	(x)		ROE (%)		R	OCE (%)
Companies	(Rs)	(Rs)	(Rs.bn)	кесо	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E
Ashok Leyland	80	89	236	Buy	NM	23.7	15.3	32.3	11.8	8.4	0.1	13.2	18.8	1.8	14.0	19.7
Atul Auto	156	258	3	Buy	20.7	6.8	5.4	11.7	4.5	3.2	5.3	14.9	16.5	7.3	19.5	21.7
Bajaj Auto	2,921	3,976	845	Buy	19.5	14.4	12.6	15.1	10.2	8.6	20.8	25.7	26.5	26.5	32.9	34.0
Eicher Motors	2,137	2,754	584	Buy	39.1	20.9	17.4	27.3	14.6	11.9	14.2	23.0	23.1	18.3	27.3	27.2
Escorts	1,188	1,256	160	Buy	22.3	16.5	13.7	13.7	10.2	8.2	12.7	13.7	14.6	16.8	17.8	18.9
Hero Motocorp	2,894	3,839	578	Buy	20.5	15.5	13.8	12.9	9.6	8.4	19.7	24.6	25.3	25.3	31.6	32.5
Mahindra & Mahindra	592	718	736	Buy	24.6	15.5	13.1	13.4	9.2	7.7	8.0	11.8	12.8	10.0	14.5	15.8
Maruti Suzuki	7,118	8,216	2,150	Buy	49.4	27.0	21.7	32.5	17.1	13.5	8.8	15.0	17.2	11.2	19.2	21.9
Tata Motors	132	196	436	Buy	NM	9.5	5.7	5.6	3.5	3.0	-13.5	8.8	13.0	1.2	7.8	9.9
TVS Motor	422	398	201	Sell	50.6	29.2	22.2	18.9	13.7	11.3	10.6	16.8	19.7	11.5	17.5	21.2
Amara Raja Batteries	743	863	127	Buy	19.8	15.3	12.9	10.8	8.6	7.2	16.6	19.1	20.0	21.7	24.9	26.1
Apollo Tyres	143	111	82	Hold	35.0	13.1	10.4	6.9	4.9	4.1	2.5	6.1	7.3	3.8	6.5	7.7
Exide Industries	157	205	133	Buy	19.2	14.5	12.6	9.8	7.8	6.7	10.7	13.1	13.8	14.0	17.1	18.1
Motherson Sumi	107	133	339	Buy	43.3	20.1	16.2	10.2	5.7	4.6	6.9	14.2	16.2	4.5	14.3	16.9
Bharat Forge	455	537	212	Buy	56.8	25.2	18.9	27.6	15.6	12.3	6.8	14.4	17.3	7.1	13.7	16.9

Key Financials (Standalone)

Income Statement

Y/E Mar (Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
Revenue	336,505	288,361	305,704	363,495	398,246
Expenditure	287,205	248,781	267,144	313,093	342,124
EBITDA	49,301	39,580	38,560	50,402	56,123
Depreciation	6,020	8,180	7,110	7,956	8,660
EBIT	43,281	31,400	31,450	42,447	47,462
Other Income	6,913	7,783	5,966	7,029	7,967
Interest expenses	86	220	231	277	333
РВТ	50,107	38,963	37,184	49,199	55,096
Тах	16,259	7,122	8,924	11,808	13,223
Extraordinary Items	0	4,491	0	0	0
Minority Int./Income from Assoc.	0	0	0	0	0
Reported Net Income	33,849	36,333	28,260	37,391	41,873
Adjusted PAT	33,849	31,841	28,260	37,391	41,873

Balance Sheet

Y/E Mar (Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
Equity share capital	400	400	400	400	400
Reserves & surplus	128,172	140,965	145,376	157,975	172,084
Net worth	128,571	141,364	145,776	158,375	172,484
Minority Interest	0	0	0	0	0
Loan Funds	0	0	0	0	0
Net deferred tax liability	5,365	3,928	4,300	4,792	5,343
Total Liabilities	133,936	145,292	150,076	163,167	177,827
Net block	46,186	57,025	54,795	53,818	55,157
Investment	59,686	82,227	88,227	99,227	113,227
Current Assets	65,121	44,829	47,261	55,765	60,171
Cash & bank balance	1,365	2,419	3,826	4,119	3,587
Other Current Assets	8,931	6,348	6,729	8,001	8,766
Current liabilities & Provision	42,476	42,201	44,739	53,197	58,282
Net current assets	22,646	2,628	2,522	2,568	1,889
Misc. exp	0	0	0	0	0
Total Assets	133,936	145,292	150,076	163,167	177,827

Y/E Mar (Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
PBT (Ex-Other income) (NI+Dep)	43,195	37,954	31,219	42,169	47,129
Other Non-Cash items	0	0	0	0	0
Chg in working cap	(19,189)	12,027	1,723	200	375
Operating Cashflow	2,878	46,318	35,311	45,419	48,594
Capital expenditure	(9,179)	(13,586)	(6,000)	(10,000)	(10,000)
Free Cash Flow	(6,301)	32,732	29,311	35,419	38,594
Investments	18,758	(18,926)	(6,000)	(11,000)	(14,000)
Other Investing Cash Flow	3,633	3,681	(5,966)	(7,029)	(7,967)
Investing Cashflow	20,124	(21,048)	(12,000)	(21,000)	(24,000)
Equity Capital Raised	20	1	0	0	0
Loans Taken / (Repaid)	0	0	0	0	0
Dividend paid (incl tax)	(22,874)	(23,325)	(21,673)	(23,848)	(24,792)
Other Financing Cash Flow	(111)	(672)	0	0	0
Financing Cashflow	(23,051)	(24,216)	(21,904)	(24,126)	(25,125)
Net chg in cash	(49)	1,054	1,407	293	(531)
Opening cash position	1,413	1,365	2,419	3,826	4,119
Closing cash position	1,365	2,419	3,826	4,119	3,587

Profitability (%)	FY19	FY20	FY21E	FY22E	FY23E
EBITDA Margin	14.7	13.7	12.6	13.9	14.1
EBIT Margin	12.9	10.9	10.3	11.7	11.9
Effective Tax Rate	32.4	18.3	24.0	24.0	24.0
Net Margin	10.1	11.0	9.2	10.3	10.5
ROCE	39.1	28.1	25.3	31.6	32.5
ROE	27.5	23.6	19.7	24.6	25.3
RoIC	78.4	50.4	56.8	80.3	89.8
Per Share Data (Rs)	FY19	FY20	FY21E	FY22E	FY23E
EPS	169.5	159.4	141.5	187.2	209.6
CEPS	199.6	200.4	177.1	227.0	253.0
BVPS	643.7	707.7	729.8	792.9	863.5
DPS	87.0	90.0	99.0	103.0	115.3
Valuations (x)	FY19	FY20	FY21E	FY22E	FY23E
PER	17.1	18.2	20.5	15.5	13.8
P/CEPS	14.5	14.4	16.3	12.7	11.4
P/BV	4.5	4.1	4.0	3.7	3.4
EV / Sales	1.6	1.8	1.7	1.4	1.2
EV / EBITDA	10.7	12.7	12.9	9.6	8.4
Dividend Yield (%)	3.0	3.1	3.4	3.6	4.0
Gearing Ratio (x)	FY19	FY20	FY21E	FY22E	FY23E
Net Debt/ Equity	(0.4)	(0.5)	(0.6)	(0.6)	(0.6)
Net Debt/EBIDTA	(1.0)	(1.9)	(2.1)	(1.8)	(1.9)
Working Cap Cycle (days)	23.1	0.3	(1.6)	(1.6)	(1.6)
Growth (%)	FY19	FY20	FY21E	FY22E	FY23E
Revenue	4.4	(14.3)	6.0	18.9	9.6
EBITDA	(6.6)	(19.7)	(2.6)	30.7	11.3
EBIT	(8.4)	(27.5)	0.2	35.0	11.8
PAT	(8.5)	7.3	(22.2)	32.3	12.0
	Q2FY20	Q3FY20	Q4FY20	Q1FY21	Q2FY21
Quarterly (Rs mn)	QZF 1ZU				
Quarterly (Rs mn) Revenue				29.715	
Revenue	75,707	69,967	62,384	29,715 1.081	93,673
Revenue EBITDA	75,707 11,011	69,967 10,390	62,384 6,599	1,081	93,673 12,864
Revenue EBITDA EBITDA Margin (%)	75,707 11,011 14.5	69,967 10,390 14.8	62,384 6,599 10.6	1,081 3.6	93,673 12,864 13.7
Revenue EBITDA EBITDA Margin (%) PAT	75,707 11,011 14.5 9,198	69,967 10,390 14.8 8,804	62,384 6,599 10.6 6,207	1,081 3.6 613	93,673 12,864 13.7 9,535
Revenue EBITDA EBITDA Margin (%)	75,707 11,011 14.5	69,967 10,390 14.8	62,384 6,599 10.6	1,081 3.6	93,673 12,864 13.7
Revenue EBITDA EBITDA Margin (%) PAT EPS (Rs)	75,707 11,011 14.5 9,198	69,967 10,390 14.8 8,804	62,384 6,599 10.6 6,207	1,081 3.6 613	93,673 12,864 13.7 9,535 47.7
Revenue EBITDA EBITDA Margin (%) PAT EPS (Rs) Source: Company, Emkay Research	75,707 11,011 14.5 9,198 46.0	69,967 10,390 14.8 8,804 44.1	62,384 6,599 10.6 6,207 31.1	1,081 3.6 613 3.1	93,673 12,864 13.7 9,535 47.7 Sep-20
Revenue EBITDA EBITDA Margin (%) PAT EPS (Rs) Source: Company, Emkay Research Shareholding Pattern (%)	75,707 11,011 14.5 9,198 46.0 Sep-19	69,967 10,390 14.8 8,804 44.1 Dec-19	62,384 6,599 10.6 6,207 31.1 Mar-20	1,081 3.6 613 3.1 Jun-20	93,673 12,864 13.7 9,535 47.7 Sep-20 34.8
Revenue EBITDA EBITDA Margin (%) PAT EPS (Rs) Source: Company, Emkay Research Shareholding Pattern (%) Promoters	75,707 11,011 14.5 9,198 46.0 Sep-19 34.6	69,967 10,390 14.8 8,804 44.1 Dec-19 34.6	62,384 6,599 10.6 6,207 31.1 Mar-20 34.6	1,081 3.6 613 3.1 Jun-20 34.8	93,673 12,864 13.7 9,535

Source: Capitaline

RECOMMENDATION HISTORY TABLE

Date	Closing Price	ТР	Period (months)	Rating	Analyst
11-Oct-20	3,327	3,701	12m	Buy	Raghunandhan NL
28-Sep-20	3,089	3,701	12m	Buy	Raghunandhan NL
15-Sep-20	3,037	3,701	12m	Buy	Raghunandhan NL
28-Aug-20	3,059	2,798	12m	Hold	Raghunandhan NL
15-Aug-20	2,804	2,798	12m	Hold	Raghunandhan NL
29-Jun-20	2,504	2,530	12m	Hold	Raghunandhan NL
10-Jun-20	2,292	2,530	12m	Hold	Raghunandhan NL
4-May-20	2,001	2,313	12m	Hold	Raghunandhan NL
13-Apr-20	1,919	2,313	12m	Hold	Raghunandhan NL
27-Feb-20	2,110	2,670	12m	Hold	Raghunandhan NL
20-Feb-20	2,240	2,670	12m	Hold	Raghunandhan NL
7-Feb-20	2,443	2,800	12m	Hold	Raghunandhan NL
30-Jan-20	2,482	3,150	12m	Hold	Raghunandhan NL
27-Dec-19	2,442	3,150	12m	Hold	Raghunandhan NL
27-Nov-19	2,523	3,150	12m	Hold	Raghunandhan NL
1-Nov-19	2,707	3,150	12m	Hold	Raghunandhan NL
30-Oct-19	2,685	3,150	12m	Hold	Raghunandhan NL
23-Oct-19	2,713	3,150	12m	Hold	Raghunandhan NL
1-Oct-19	2,688	3,200	12m	Hold	Raghunandhan NL
26-Sep-19	2,760	3,200	12m	Hold	Raghunandhan NL
23-Sep-19	2,820	3,200	12m	Hold	Raghunandhan NL
3-Sep-19	2,557	2,380	12m	Hold	Raghunandhan NL
28-Aug-19	2,569	2,380	12m	Hold	Raghunandhan NL
31-Jul-19	2,356	2,380	12m	Hold	Raghunandhan NL
1-Jul-19	2,617	2,585	12m	Hold	Raghunandhan NL
27-Jun-19	2,598	2,585	12m	Hold	Raghunandhan NL
3-Jun-19	2,840	2,585	12m	Hold	Raghunandhan NL
29-May-19	2,726	2,585	12m	Hold	Raghunandhan NL
2-May-19	2,552	2,585	12m	Hold	Raghunandhan NL
26-Apr-19	2,604	2,585	12m	Hold	Raghunandhan NL
27-Mar-19	2,543	2,700	12m	Hold	Raghunandhan NL
4-Feb-19	2,780	2,700	12m	Hold	Raghunandhan NL
31-Jan-19	2,614	2,700	12m	Hold	Raghunandhan NL
27-Dec-18	3,129	3,350	12m	Hold	Raghunandhan NL
16-Oct-18	2,895	3,560	12m	Buy	Raghunandhan NL
3-Aug-18	3,251	4,130	12m	Buy	Raghunandhan NL
26-Jul-18	3,137	4,130	12m	Buy	Raghunandhan NL
2-May-18	3,664	4,660	12m	Buy	Raghunandhan NL
6-Feb-18	3,542	4,710	12m	Buy	Raghunandhan NL
2-Nov-17	3,736	4,820	12m	Buy	Raghunandhan NL

Source: Company, Emkay Research

RECOMMENDATION HISTORY CHART



Source: Bloomberg, Company, Emkay Research



Analyst: Raghunandhan NI

Contact Details

raghunandhan.nl@emkayglobal.com

+91 22 6624 2428

Sector

Automobiles and Ancillaries

Analyst bio

Raghu holds an MBA and comes with total 11 years of research experience. His team currently covers 14 stocks in the Indian Automobiles and Ancillaries space.

Emkay Alpha Portfolio – Automobiles & Auto Ancillaries

EAP	sector	portfolio

Company Name	BSE200 Weight	EAP Weight	OW/UW (%)	OW/UW (bps)	EAP Weight (Normalised)
Auto & Auto Ancillaries	5.38	5.38	0%	0	100.00
Amara Raja Batteries	0.09	0.00	-100%	-9	0.00
Apollo Tyres	0.07	0.07	0%	0	1.34
Ashok Leyland	0.17	0.29	65%	11	5.34
Atul Auto	0.00	0.00	NA	0	0.00
Bajaj Auto	0.59	0.59	0%	0	10.98
Bharat Forge	0.18	0.24	32%	6	4.37
Eicher Motors	0.46	0.51	12%	5	9.52
Escorts	0.00	0.00	NA	0	0.00
Exide Industries	0.11	0.00	-100%	-11	0.00
Hero Motocorp	0.59	0.64	8%	5	11.89
Mahindra & Mahindra	0.89	0.89	0%	0	16.54
Maruti Suzuki India	1.48	1.47	0%	0	27.34
Motherson Sumi	0.20	0.20	0%	0	3.65
Tata Motors	0.37	0.37	0%	0	6.80
Tata Motors DVR	0.04	0.04	0%	0	0.78
TVS Motor	0.13	0.08	-41%	-5	1.44
Cash	0.00	0.00	NA	0	0.00

Source: Emkay Research


High Conviction/Strong Over Weight High Conviction/Strong Under Weight

Sector portfolio NAV

	Base					Latest
	1-Apr-19	29-Jan-20	29-Apr-20	29-Jul-20	28-Sep-20	28-Oct-20
EAP - Auto & Auto Ancillaries	100.0	95.3	62.3	82.6	91.0	91.7
BSE200 Neutral Weighted Portfolio (ETF)	100.0	96.8	64.2	85.8	93.2	93.7

*Performance measurement base date 1st April 2019 Source: Emkay Research

,



Source: Emkay Research

Please see our model portfolio (Emkay Alpha Portfolio): Nifty

Please see our model portfolio (Emkay Alpha Portfolio): SMID

"Emkay Alpha Portfolio – SMID and Nifty are a supporting document to the Emkay Alpha Portfolios Report and is updated on regular intervals"

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	Over 15%
HOLD	Between -5% to 15%
SELL	Below -5%

Completed Date: 30 Oct 2020 05:20:24 (SGT) Dissemination Date: 30 Oct 2020 05:21:24 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

• This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.

• Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

Disclaimer for U.S. persons only: This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investors. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate¹ does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of October 29, 2020
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of October 29, 2020.
- 5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the October 29, 2020
- 6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
- 8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the October 29, 2020

RESTRICTIONS ON I	DISTRIBUTION
General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6 th Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

Emkay Global Financial Services Ltd. CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com